SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

The FDA's issuance of a Complete Response Letter (CRL) for Regenxbio's RGX-121 gene therapy for Hunter syndrome is driving intense conversation, with the community expressing significant concerns about the trial design, financial implications, and potential dilution amidst broader scrutiny of gene therapy development.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl (KD) is in focus following the abrupt departure of its CFO and general counsel amidst an accounting review and delayed regulatory filings, triggering a severe sell-off. The community is debating whether the IT infrastructure provider's over 50% stock drop is an extreme overreaction and a buying opportunity, or a justified response to serious governance concerns.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

FISV is trending intensely ahead of its earnings, with the community sharply divided between those anticipating a strong rebound fueled by perceived undervaluation, recent institutional accumulation, and new leadership's strategic moves, and those fearing another significant drop due to past disappointments, heavy put option activity, and ongoing fintech sector concerns.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is experiencing significant volatility following its mixed Q4 earnings, which showed an EPS beat but a revenue miss and conservative 2026 guidance prioritizing prudent risk management. While the market is punishing PGY, many in the community view the dramatic sell-off as an extreme overreaction given the company's profitability, strong fundamentals, and historically low valuation compared to peers in the fintech and AI sectors.

Silvercorp Metals, Inc. engages in the acquisition, exploration, development, and mining of mineral properties and Environmental, Social and Governance practices. It operates through Mining and Administrative segments. The Mining segment includes Henan Luoning, Guangdong, and others. Its products include Silverbearing lead and Zinc Concentrates.The Administrative segment focuses on Vancouver and Beijing. The company was founded by Rui Feng on October 31, 1991 and is headquartered in Vancouver, Canada.

Silvercorp Metals Inc

Silvercorp Metals Inc.

Silvercorp Metals is trending due to a blowout quarterly earnings report that exceeded estimates, with the community actively discussing its perceived undervaluation and anticipating a significant price surge, bolstered by strong precious metals market conditions.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group (CRDO) is surging after pre-announcing preliminary Q3 revenue significantly above prior guidance and consensus, coupled with a robust outlook for sequential growth into fiscal year 2027. The community is vigorously discussing this strong performance, highlighting its crucial role in the ongoing AI data center buildout and the massive capital expenditure increases from hyperscalers, expecting continued upward momentum.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending following its robust Q4 earnings beat, though a mixed Q1 outlook is fueling debate among investors between short-term caution and long-term optimism regarding its pivotal role in advanced AI and data center packaging, bolstered by strategic investments and CHIPS Act funding.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending amid anticipation for its upcoming earnings and significant market speculation regarding the uncertain fate of a House-passed bill to extend ACA subsidies; the community remains sharply divided, with some foreseeing a major re-rating due to policy tailwinds and execution, while others highlight financial challenges and broader sector headwinds.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the Design Automation and Design IP segments. The Design Automation segment includes silicon design, verification of products and services, and Ansys products, and system integration of products and services. The Design IP segment refers to interface, foundation, security, and embedded processor IP, IP subsystems, and IP implementation services that serve companies primarily in the semiconductor and electronics industries. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys Inc

Synopsys is trending after Nvidia's $2 billion strategic investment and expanded partnership, which the community views as a significant validation of its indispensable role in AI-driven chip design and engineering. This collaboration solidifies Synopsys' position as a critical enabler in the booming semiconductor industry.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

CRO is trending following news of Trump Media's ($DJT) partnership with crypto.com/us for digital token distribution on the Cronos chain, with discussions also highlighting its potential inclusion and significant weighting in a proposed Crypto ETF. This development is driving considerable community debate, with some anticipating substantial growth while others express skepticism about the coin's future trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - Still a Buy?

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - What's Next...

Regencell Bioscience (NASDAQ:RGC) Trading Down 10.1% - Here's Why

Regencell Bioscience (NASDAQ:RGC) Shares Down 10.1% - Time to Sell...

Regencell Bioscience Holdings Limited (NASDAQ:RGC) Short Interest Down 28.1% in January

Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest...

Regencell Bioscience (NASDAQ:RGC) Stock Price Down 7.4% - Here's What Happened

Regencell Bioscience (NASDAQ:RGC) Shares Down 7.4% - What's Next...

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - What's Next?

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Here's Why...

Regencell Bioscience (NASDAQ:RGC) Trading Up 30% - Here's What Happened

Regencell Bioscience (NASDAQ:RGC) Shares Up 30% - Here's Why...

Regencell Bioscience (NASDAQ:RGC) Trading Down 7.8% - What's Next?

Regencell Bioscience (NASDAQ:RGC) Trading Down 7.8% - Here's What Happened...

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Should You Sell?

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Time to Sell...

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - Here's What Happened

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - Still a Buy...

<ul class="summary-bullets"><li>Regencell stated in an October SEC filing that it may be required to curtail or discontinue its operations in the future.</li><li>In the 2025 and 2024 fiscal years, Regencell reported a net loss of $3.58 million and $4.36 million, respectively.</li><li>The company had indicated that it anticipates incurring additional losses before realizing any revenues.</li></ul>Shares of Regencell Bioscience Holdings (RGC) have been drawing significant investor attention after gaining nearly 152% in the first four trading sessions of 2026.Following Wednesday’s relentless rally, the shares continued to climb in Thursday’s pre-market trade as well, rising by over 20% at the time of writing.While the bulk of the recent surge has come in 2026, RGC stock is still up nearly 218% since October 31, despite the company flagging a “substantial doubt” about its ability to continue as a going concern.<figure class="image"><img src="https://news.stocktwits-cdn.com/RGC_stock_chart_jpg_b4d92bf445.webp" alt="RGC stock performance from Jan. 1, 2025 to Jan. 7, 2025" width="1516" height="417"><figcaption>RGC stock performance from Jan. 1, 2025 to Jan. 7, 2025 | Koyfin</figcaption></figure><h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits regarding Regencell Bioscience was trending in the ‘bullish’ territory at the time of writing.One bullish user thinks that traders shorting the stock are in “huge trouble now.”<stembedurl>https://stocktwits.com/elbardinnyo/message/641188884</stembedurl>Another user said they treat it as a momentum-only stock.<stembedurl>https://stocktwits.com/Faniabh/message/641180065</stembedurl><h2 class="st-heading-2">RGC’s Going Concern Flag</h2>In a filing with the U.S. Securities and Exchange Commission in October 2025, the company said that there is a “substantial doubt” about its ability to continue as a going concern.It added that this indicates the company may be required to curtail or discontinue its operations in the future.“If we discontinue our operations, you may lose all of your investment,” Regencell said, adding that it anticipates incurring additional losses before realizing any revenues. In the 2025 and 2024 fiscal years, Regencell reported a net loss of $3.58 million and $4.36 million, respectively.Regencell is an early-stage company focusing on research, development, and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder.<a href="https://stocktwits.com/symbol/RGC">RGC stock</a> is up 152% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-hele-stock-falling-today/cmUb4SeR4Po">HELE Stock Slides Pre-market As Tariff Headwinds Trigger FY26 Earnings Guidance Cut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

RGC Stock Gains 20% Pre-Market — Retail Says Shorts Are In ‘Huge Trouble’

Regencell shares are up nearly 218% since October 31, despite the company flagging a “substantial doubt” about its ability to continue as a going concern.

Why Is RGC Stock Soaring Today?

Equity

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

RGC
Regencell Bioscience Holdings Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RGC News

RGCRegencell Bioscience Holdings Ltd